Results

Total Results: 3,357 records

Showing results for "aspirin".

461. Announcements | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/news/announcements?page=5
     January 13, 2022 - Public Comment on Draft Recommendation Statement, Draft Evidence Review, and Draft Modeling Report: Aspirin … Use to Prevent Cardiovascular Disease 2021-10-12 Final Recommendation Statement: Aspirin

462. AHRQ CDS TEP CDSC Updates - CDSC Knowledge Management Portal (pdf file)
     digital.ahrq.gov/sites/default/files/docs/page/3-2010_0201_TEP_Demos_KMPortal.pdf
     January 01, 2010 - Message Request with the Message "Because you have diabetes or heart disease, you might benefit from aspirin … If you are not taking aspirin regularly, you may want to discuss whether or not you should take aspirin … Substance Administration Request with product code "C0004057" , route "C38288" , alternative text "Start aspirin

463. Hlthy_Hrts_MsrmntHndout (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/measure-handout-mw.pdf
     May 07, 2018 - Numerator Statement Denominator Statement A CMS164v4 0068 Ischemic Vascular Disease (IVD): Use of Aspirin … Antithrombotic Domain: Clinical Process/Effectiveness Patients who have documentation of use of aspirin

464. HealthyHearts NYC Primary Care Partnerships Advancing Heart Health (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/recruitment-slides-ny.pdf
     August 18, 2015 - cardiovascular disease prevention Project Goal Project Measures • Improving adherence to ABCS: – Aspirin … pressure control – Cholesterol management – Smoking cessation 6/20/2018 www.chcanys.org 8 Aspirin … Percentage of patients aged 18 years and older with Ischemic Vascular Disease with documented use of aspirin … EvidenceNow: Advancing Heart Health in Primary Care Project Goal Project Goal Project Measures Aspirin

465. Comparative Effectiveness Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Fever;Pain Pain: 650-1000 mg up to 4g/day Peds: 10-15 mg/kg/dose up to 5 doses/day aspirin Elimination … Trials of rofecoxib vs NSAIDs Author year Aspirin permitted? … Excluded aspirin 81 mg users. 25 diclofenac 50 tid 693 52 Appendix F. … use; topical product use at the application site; history of sensitivity to any of the study drugs, acetylsalicylic … acid or other NSAID; severe, uncontrolled cardia, renal hepatic or other systemic disease; documented

466. Comparative Effectiveness Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Fever;Pain Pain: 650-1000 mg up to 4g/day Peds: 10-15 mg/kg/dose up to 5 doses/day aspirin Elimination … Trials of rofecoxib vs NSAIDs Author year Aspirin permitted? … Excluded aspirin 81 mg users. 25 diclofenac 50 tid 693 52 Appendix F. … use; topical product use at the application site; history of sensitivity to any of the study drugs, acetylsalicylic … acid or other NSAID; severe, uncontrolled cardia, renal hepatic or other systemic disease; documented

467. Recommendation: Peripheral Artery Disease and Cardiovascular Disease: Screening and Risk Assessment With the Ankle-Brachial Index | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/peripheral-artery-disease-in-adults-screening-with-the-ankle-brachial-index
     July 10, 2018 - One study, Aspirin for Asymptomatic Atherosclerosis (N = 3350), enrolled men and women aged 50 to 75 … Two trials addressed the harms of aspirin treatment in asymptomatic persons. … bleeding events requiring hospitalization in the aspirin therapy vs placebo group (hazard ratio, 1.71 … Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. … Fowkes FG, Price JF, Stewart MC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists.

468. Angina-Heart-Attack-Treatments Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_executive.pdf
     January 01, 2014 - Aspirin and Antiplatelet Agents In the absence of contraindications, aspirin is currently recommended … mg; high-dose aspirin ranged from 150 mg to 325 mg. 4 Figure A. … Do the effectiveness and safety vary based on the dose of aspirin used? b. … Key Points: Low-Dose Versus High-Dose Aspirin • In the postdischarge setting, high-dose aspirin was … bHRs less than 1 favor high-dose aspirin; HRs greater than 1 favor low-dose aspirin. Table L.

469. Angina-Heart-Attack-Treatments Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_executive.pdf
     January 01, 2014 - Aspirin and Antiplatelet Agents In the absence of contraindications, aspirin is currently recommended … mg; high-dose aspirin ranged from 150 mg to 325 mg. 4 Figure A. … Do the effectiveness and safety vary based on the dose of aspirin used? b. … Key Points: Low-Dose Versus High-Dose Aspirin • In the postdischarge setting, high-dose aspirin was … bHRs less than 1 favor high-dose aspirin; HRs greater than 1 favor low-dose aspirin. Table L.

470. Announcements | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/news/announcements?page=10
     April 07, 2020 - Visual Acuity and Glaucoma in Adults 2020-02-13 Public Comment on Draft Research Plan: Aspirin … Illicit Drug Use in Children, Adolescents, and Young Adults 2019-10-01 Final Research Plan: Aspirin

471. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/acqA29t-vpgphFscNPEfG8
     January 01, 2020 - One study, Aspirin for Asymptomatic Atherosclerosis (N = 3350), enrolled men and women aged 50 to 75 … Two trials addressed the harms of aspirin treatment in asymp- tomatic persons. … bleeding events requiring hospitalization in the aspirin therapy vs placebo group (hazard ratio, 1.71 … Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. … Fowkes FG, Price JF, Stewart MC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists.

472. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - – LMWH vs. aspirin: Based primarily on a very large propensity-score-adjusted NRCS, LMWH and aspirin … N=1533) compared LMWH versus antiplatelet drug (aspirin). … Across this study set, 23 interventions were evaluated (apixaban, aspirin, aspirin plus IPC, aspirin … plus VFP were directly compared with aspirin only; aspirin plus IPC was directly compared with enoxaparin … However, one RCT of aspirin versus the combination of aspirin plus VFP did not connect to the network

473. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - – LMWH vs. aspirin: Based primarily on a very large propensity-score-adjusted NRCS, LMWH and aspirin … N=1533) compared LMWH versus antiplatelet drug (aspirin). … Across this study set, 23 interventions were evaluated (apixaban, aspirin, aspirin plus IPC, aspirin … plus VFP were directly compared with aspirin only; aspirin plus IPC was directly compared with enoxaparin … However, one RCT of aspirin versus the combination of aspirin plus VFP did not connect to the network

474. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - – LMWH vs. aspirin: Based primarily on a very large propensity-score-adjusted NRCS, LMWH and aspirin … N=1533) compared LMWH versus antiplatelet drug (aspirin). … Across this study set, 23 interventions were evaluated (apixaban, aspirin, aspirin plus IPC, aspirin … plus VFP were directly compared with aspirin only; aspirin plus IPC was directly compared with enoxaparin … However, one RCT of aspirin versus the combination of aspirin plus VFP did not connect to the network

475. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - – LMWH vs. aspirin: Based primarily on a very large propensity-score-adjusted NRCS, LMWH and aspirin … N=1533) compared LMWH versus antiplatelet drug (aspirin). … Across this study set, 23 interventions were evaluated (apixaban, aspirin, aspirin plus IPC, aspirin … plus VFP were directly compared with aspirin only; aspirin plus IPC was directly compared with enoxaparin … However, one RCT of aspirin versus the combination of aspirin plus VFP did not connect to the network

476. Clinical Summary: Screening for Cardiovascular Disease Risk With Electrocardiography (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/tHHBn5j3PD_Bnjk7q6tACS
     June 05, 2018 - usually treated w ith a combination of diet and exercise modif ications, lipid-low ering medications, aspirin … In addition, the USPSTF recommends low -dose aspirin use in certain persons at increased risk of CVD

477. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_executive.pdf
     January 01, 2006 - acid derivatives (aspirin and salsalate) were considered a separate subgroup. … Oral agents include: • Acetaminophen • Aspirin • Celecoxib • Choline magnesium trisalicylate • … • No studies evaluated the comparative efficacy of salsalate or aspirin vs. a nonaspirin NSAID. … • Aspirin • Aspirin is associated with a lower risk of thromboembolic events and a higher risk of … between celecoxib and nonselective NSAIDs in the subgroup of patients who took aspirin

478. Layout 1 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_executive.pdf
     January 01, 2006 - acid derivatives (aspirin and salsalate) were considered a separate subgroup. … Oral agents include: • Acetaminophen • Aspirin • Celecoxib • Choline magnesium trisalicylate • … • No studies evaluated the comparative efficacy of salsalate or aspirin vs. a nonaspirin NSAID. … • Aspirin • Aspirin is associated with a lower risk of thromboembolic events and a higher risk of … between celecoxib and nonselective NSAIDs in the subgroup of patients who took aspirin

479. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/peripheral-artery-disease-pad-defined-as-peripheral-artery-disease-of-the-lower-extremities-1-does-aspirin-reduce-the-risk-of-adverse-cardiovascular-events-mi-stroke-cardiovascular-death-in-patients-with-pad-is-there-a-differ
     January 20, 2011 - Peripheral Artery Disease (PAD) defined as peripheral artery disease of the lower extremities Does aspirin … Is clopidogrel more effective than aspirin in reducing adverse cardiovascular events in PAD? … would like to see compared: For questions 1 and 2, comparisons between no antiplatelet therapy and aspirin

480. SRDR - Systematic Review Data Repository |
     srdr.ahrq.gov/projects/1671/studies/196398
     January 01, 2010 - Other Your Feedback: Submit Reset Cancel Study Preview Study Title and Description Aspirin … Primary Publication Information Comments ( 0 ) | Post/View Title Data Title Aspirin